Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases